Abraham Abuchowski

Biochemistry, Genetics and Molecular Biology · Life Sciences

28h-index5.4kcitations61works3.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Heme Oxygenase-1 and Carbon Monoxide(13), Hemoglobin structure and function(11), Acute Lymphoblastic Leukemia research(10), Neonatal Health and Biochemistry(8), Hemoglobinopathies and Related Disorders(6)

Publications61 total

Reduction of Immunogenicity and Extension of Circulating Half-Life of Peptides and Proteins
2024· 3 cited
Recruitment of monocytes primed to express heme oxygenase-1 ameliorates pathological lung inflammation in cystic fibrosis
Experimental & Molecular Medicine·2022· 7 citedOpen Access
558: Carbon monoxide–based therapy primes macrophages to express HO-1 and to resolve lung hyper-inflammation in cystic fibrosis
Journal of Cystic Fibrosis·2021Open Access
Targeting the HO-1/CO Pathway with Sanguinate: Toward Development of a Novel Anti-inflammatory Therapy for Cystic Fibrosis (CF) Lung Disease
2019· 1 cited
Pegylated Carboxyhemoglobin Bovine (SANGUINATE®) Restores RBCs Roundness and Reduces Pain during a Sickle Cell Vaso-Occlusive Crisis
Blood·2017· 5 cited
A phase Ib, open‐label, single arm study to assess the safety, pharmacokinetics, and impact on humoral sensitization of <scp>SANGUINATE</scp> infusion in patients with end‐stage renal disease
Clinical Transplantation·2017· 17 cited
A Phase I study to determine safety, pharmacokinetics, and pharmacodynamics of ANF-RHO™, a novel PEGylated granulocyte colony-stimulating factor, in healthy volunteers
Investigational New Drugs·2017· 3 cited
SANGUINATE (PEGylated Carboxyhemoglobin Bovine): Mechanism of Action and Clinical Update
Artificial Organs·2017· 65 cited
A Phase Ib open label, randomized, safety study of SANGUINATE™ in patients with sickle cell anemia
Revista Brasileira de Hematologia e Hemoterapia·2016· 54 citedOpen Access
Phase I pharmacokinetic and pharmacodynamic results of novel anti-neutropenic factor for the prevention and treatment of febrile neutropenia.
Journal of Clinical Oncology·2016
PEGylated Bovine Carboxyhemoglobin (SANGUINATE™): Results of Clinical Safety Testing and Use in Patients
Advances in experimental medicine and biology·2016· 50 cited
Peg-Cohb Mediated Carbon Monoxide and Oxygen Transfer to Hypoxic Red Blood Cells Prevent, Slow, and/or Reverse Sickling in Vitro.
Blood·2015
ANF-Rho: A Dose-Ranging Phase I Study to Determine Safety, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers
Blood·2015
Potential use of PEG-HbCO in severe anemia.
Journal of Clinical Oncology·2015
PEGylated Carboxyhemoglobin Bovine (SANGUINATE): Results of a Phase I Clinical Trial
Artificial Organs·2014· 69 cited
Carbon monoxide form of PEGylated hemoglobin protects myocardium against ischemia/reperfusion injury in diabetic and normal mice
Artificial Cells Nanomedicine and Biotechnology·2013· 40 citedOpen Access
Early Treatment of Transient Focal Cerebral Ischemia with Bovine PEGylated Carboxy Hemoglobin Transfusion
Artificial Cells Blood Substitutes and Biotechnology·2010· 37 citedOpen Access
Novel therapeutics from modern biotechnology : from laboratory to human testing
Springer eBooks·1999· 3 cited
Strategies for Dealing With the Immunogenicity of Therapeutic Proteins
Handbook of experimental pharmacology·1999· 1 cited
The Search for Blood Substitutes
Scientific American·1998· 40 cited
page 1 of 4Next →

Frequent Co-authors

Fergal Davis(11), Frank F. Davis(9), T. van Es(6), Nicholas C. Palczuk(6), Mary L. Nucci(6), David Kafkewitz(6), Anna T. Viau(5), Hemant K. Misra(4), Robert Shorr(3), Ronald Jubin(3), Michael S. Hershfield(2), Michael Greenberg(2), Christine L. Hatem(2), Joanne Kurtzberg(2), Ai Kobayashi(2), Davis Ff(2), Y K Park(2), Kenneth V. Savoca(2), Friedericke Kazo(2), John Berryman(2)